Dr. Amit Mandoli, Ph.D.
Associate Professor , Department of Biotechnology
-
National Institute of Pharmaceutical Education and Research-Ahmedabad -
amitmandoli[at]niperahm[dot]ac[dot]in, amitmandoli[at]niperahm[dot]res[dot]in -
+91 79-65181200 -
Gandhinagar -
Gujarat
Research Interest
Research Area:
- Cancer and Hematological Disorders: Oral squamous cell carcinoma (OSCC), acute myeloid leukemia (AML), and sickle cell anemia.
- Functional Genomics, Epigenomics and Proteomics: Next-generation sequencing (NGS), transcriptomics (RNA-seq), epigenetics (ChIP-seq, ATAC-seq), chromatin interactions (Hi-C, 4C, HiChIP), spatial transcriptomics and quantitative mass spectrometry-based proteomics.
- Genome Editing and Gene Regulation: CRISPR-Cas9/dCas9-based genome editing assays, including gene knockout, knock-in, functional genomic screens, and promoter/enhancer pull-down assays.
- Disease Modelling: Induced pluripotent stem cells (iPSCs), and patient-derived organoids (PDOs) for cancer disease modelling and differentiation.
- Translational Drug Discovery: Target identification and validation, drug screening and repurposing, and hit-to-lead studies.
Experience
- February 2025 - Present
Associate Professor
NIPER- Ahmedabad, Palaj, Gandhinagar
- February 2020 - February 2025
Assistant Professor
NIPER- Ahmedabad, Palaj, Gandhinagar
- February 2018 – February 2020
Senior Research Scientist
Duke-NUS Medical School, Singapore
- March 2017 – October 2017
Postdoc scientist
Institute for cancer research, Oslo University Hospital, Norway
- January 2012 – December 2016
Postdoc scientist
Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen, The Netherlands Honours/Awards/Grants/Consultancies
Research Grants
- Developing novel targeted therapeutics for t(8:21) acute myeloid leukemia (AML) (2021-2023). DST-SERB SRG
- Characterisation of transcriptional landscape and its functional role in Gingivo-Buccal oral squamous cell carcinoma (GB-OSCC) for targeted drug discovery (2022-2025). GSBTM
- Development and validation of Patient-derived organoids as an in-vitro drug screening model for oral cavity squamous cell carcinoma patients (2022-2025). ICMR
- Grant for Single Cell GEX from 10X Genomics, USA (2023).
- Killing two birds with one stone: dual blockade of tumor pyruvate kinase M2 and dihydrofolate reductase through hybrid molecule in oral cancer (2022-2025). ICMR
- Investigation of novel squaramide based IL-8R inhibitors and bio-instructive peptido-hydrogels for simultaneous management of metastatic oral squamous cell carcinomas and oral mucositis (2024-2028). ICMR
- Hit to Lead Optimization of Adamantane-Quinoxalone Hybrids for the Precision Chemotherapy of Acute Myeloid Leukemia (2025). ICMR
- Preclinical lead optimization of KT-32, a dual HDAC and topoisomerase IIα inhibitor, to enhance pharmacokinetic (2025). ICMR
Patent
- Polyfluorinated squaramide anticancer molecules and use after.
Patent No: 534180, Year: 2024, Country: India - Pyranoacridone compounds and process for preparation of thereof.
Patent No: 543661, Year: 2024, Country: India - Ferrocene-based pyrazolopyrimidine compounds and their uses thereof.
Patent No. 568053, Year: 2023, Country: India - Novel heterocyclic-tethered benzofulvenes: Method of preparation and their therapeutic use.
Patent Application No: 202421073889, Year: 2024, Country: India - Point of care lateral flow device for determining the presence of sickle cell anemia.
Patent Application No: 202621022444, Year: 2026, Country: India